EL7.AI
StocksMedium•16 November 2026•
3 min read

Scienture revenue reaches $1,254,577 in third quarter as REZENOPY sales begin

Key Facts

1Scienture revenue in the third quarter was $1,254,577, compared with $590,050 in the same period of 2025.
2REZENOPY contributed $924,794 of third-quarter revenue, and ARBLI contributed $329,783.
3Third-quarter gross profit was about $1.02 million, up 77.5% year over year.
4Third-quarter net loss was $6,009,447, compared with $3,607,361 in the same period of 2025.

Scienture reported results on November 16 for the third quarter ended September 30, recording revenue of $1,254,577, compared with $590,050 in the same period of 2025. Gross profit was about $1.02 million, up 77.5% year over year, according to the results statement. Revenue came as commercial sales of REZENOPY began during the quarter, alongside continued sales of ARBLI. The filing showed that REZENOPY contributed $924,794 of quarterly revenue, versus $329,783 for ARBLI. This marks the addition of a new product to the company’s sales base, while the coming period’s performance will remain tied to whether sales continue after the initial shipments.

The company said in its filing that gross product sales during the quarter were $2,433,300, before deductions of $1,178,724 for wholesale distribution fees, discounts, rebates and other adjustments to arrive at net revenue. Scienture began commercial sales of REZENOPY during the three months ended September 30, while it said in a shareholder letter that the commercial launch took place in August 2026. ARBLI received U.S. Food and Drug Administration approval in March 2025 and began marketing in the fourth quarter of that year. ARBLI revenue totaled about $729,747 in the first nine months of 2026. In the shareholder letter, the company said ARBLI wholesale unit sales increased 74% quarter over quarter, and that the product had been added to the formularies of more than ten U.S. children’s academic centers.

For the first nine months of 2026, the company recorded revenue of $1,654,541, compared with $600,308 a year earlier, while gross profit was $1.41 million, up about 145% year over year. Scienture said its net loss for the period narrowed to $12,234,082 from $13,391,931 in the corresponding nine months of 2025. But the third-quarter loss alone widened to $6,009,447, compared with $3,607,361 in the third quarter of 2025. The company used $9,514,046 in cash in operating activities during the first nine months, up from $8,204,389 in the comparable period. The figures reflect revenue growth and an improved nine-month loss, alongside a larger quarterly loss and higher operating cash use.

Revenue concentration remained high: three national distributors accounted for 100.00% of third-quarter revenue and 99.03% of revenue in the first nine months. This concentration makes order volumes from those distributors a direct factor in the company’s revenue in coming periods. Based on August 2026 IQVIA data, Scienture estimated the U.S. naloxone nasal-spray market at about $137 million annually, with about 9 million units sold each year. The company said available cash, together with revenue and financing plans, was sufficient to fund operations and obligations for at least 12 months from the date the financial statements were issued. Management tied that estimate to adoption of the two products and the possibility of raising additional financing, while the company is targeting profitability in 2027.

In a preliminary announcement dated October 13, Scienture estimated third-quarter revenue at about $1.22 million, up 256% from about $344,000 in the second quarter. Final results showed quarterly revenue of $1,254,577, compared with third-quarter 2025 revenue of $590,050. The co-CEO said the REZENOPY launch and expansion of distribution channels could support revenue growth through the end of 2026 and during 2027, and the company described profitability in 2027 as a management target. In trading ahead of the results announcement, SCNX closed at $3.20 on November 9, then at $3.04 on November 10 and November 11, and $3.01 on November 12. On November 13, it closed at $2.90, according to EL7 data.

Open on chart